RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.